Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2004

01-04-2004 | Originales

High risk Ewing's sarcomas. Effectiveness and toxicity of a regimen designed for children and used in adults

Authors: Ángel Segura Huerta, José A. Pérez-Fidalgo, Aparicio Urtasun, Pedro López-Tendero, Ángel Guerrero Zotano, Joaquín Montalar Salcedo

Published in: Clinical and Translational Oncology | Issue 3/2004

Login to get access
Metadata
Title
High risk Ewing's sarcomas. Effectiveness and toxicity of a regimen designed for children and used in adults
Authors
Ángel Segura Huerta
José A. Pérez-Fidalgo
Aparicio Urtasun
Pedro López-Tendero
Ángel Guerrero Zotano
Joaquín Montalar Salcedo
Publication date
01-04-2004
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2004
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02710118

Other articles of this Issue 3/2004

Clinical and Translational Oncology 3/2004 Go to the issue

Originales

Síndrome de supresión del antiandrógeno: estrategia terapéutica en el cáncer de próstata andrógeno-independiente

Correspondencia

Frecuencia de proctopatía postradiación en pacientes con cancer cérvico-uterino (Réplica)

Revisiones

Prolonged neoadjuvant treatment plus GM-CSF in locally advanced breast cancer: clinical and biological concepts

Announcement

Información

Editorial

La necesidad de un Pacto de Estado por la Ciencia en España

Correspondencia

Carta de D. Carlos Manuel Ortiz Mendoza con relación A un artículo de cáncer cervicouterino
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits